



## **FIMECS Presents at the 2<sup>nd</sup> Targeted Protein Degradation Conference in Japan**

Kanagawa, Japan, 25 July 2023 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Kanae Gamo, Ph.D., Chief Scientific Officer of FIMECS, will make a presentation at the 2nd Targeted Protein Degradation Conference in Japan (26-27 July 2023 in Kanagawa, Japan). Title is “Exploring E3 Ligases for Targeted Protein Degradation by Phenotypic-First Approach”. In this presentation, improvement of the RaPPIDS™ platform for expanding the landscape of E3 ligases by function-first approach that make degrader discovery more efficient will be introduced. In addition, Yusuke Tominari, Ph.D. Chief Executive Officer of FIMECS will have the Opening Remarks and facilitate the Panel Discussion. This event will be the second international conference organized by FIMECS, the first being in 2019. About 200 participants, including top-tier researchers and companies from around the world, will gather to discuss the targeted protein degradation.

For more information: <https://conference.fimecs.com/>

### **About FIMECS, Inc.**

FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. <https://www.fimecs.com/eng/>

### **About RaPPIDS™**

RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company’s proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders. Moreover, RaPPIDS™ platform enables the discovery of novel E3 ligase binders, which is expected to dramatically expand the range of target proteins that can be degraded.

###

### **FIMECS, Inc. Media and Investor Contact:**

FIMECS, Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

Tel: +81-466-96-0261

Email: [info@fimecs.com](mailto:info@fimecs.com)